Literature DB >> 28636052

Chemically induced degradation of CDK9 by a proteolysis targeting chimera (PROTAC).

Caroline M Robb1, Jacob I Contreras, Smit Kour, Margaret A Taylor, Mohammad Abid, Yogesh A Sonawane, Muhammad Zahid, Daryl J Murry, Amarnath Natarajan, Sandeep Rana.   

Abstract

Cyclin-dependent kinase 9 (CDK9), a member of the cyclin-dependent protein kinase (CDK) family, is involved in transcriptional elongation of several target genes. CDK9 is ubiquitously expressed and has been shown to contribute to a variety of malignancies such as pancreatic, prostate and breast cancers. Here we report the development of a heterobifunctional small molecule proteolysis targeting chimera (PROTAC) capable of cereblon (CRBN) mediated proteasomal degradation of CDK9. In HCT116 cells, it selectively degrades CDK9 while sparing other CDK family members. This is the first example of a PROTAC that selectively degrades CDK9.

Entities:  

Year:  2017        PMID: 28636052      PMCID: PMC5555382          DOI: 10.1039/c7cc03879h

Source DB:  PubMed          Journal:  Chem Commun (Camb)        ISSN: 1359-7345            Impact factor:   6.222


  43 in total

1.  Structural basis of lenalidomide-induced CK1α degradation by the CRL4(CRBN) ubiquitin ligase.

Authors:  Georg Petzold; Eric S Fischer; Nicolas H Thomä
Journal:  Nature       Date:  2016-02-24       Impact factor: 49.962

Review 2.  Targeted Protein Degradation by Small Molecules.

Authors:  Daniel P Bondeson; Craig M Crews
Journal:  Annu Rev Pharmacol Toxicol       Date:  2016-10-12       Impact factor: 13.820

3.  A "Click Chemistry Platform" for the Rapid Synthesis of Bispecific Molecules for Inducing Protein Degradation.

Authors:  Ryan P Wurz; Ken Dellamaggiore; Hannah Dou; Noelle Javier; Mei-Chu Lo; John D McCarter; Dane Mohl; Christine Sastri; J Russell Lipford; Victor J Cee
Journal:  J Med Chem       Date:  2017-04-17       Impact factor: 7.446

4.  Dinaciclib (SCH 727965), a novel and potent cyclin-dependent kinase inhibitor.

Authors:  David Parry; Timothy Guzi; Frances Shanahan; Nicole Davis; Deepa Prabhavalkar; Derek Wiswell; Wolfgang Seghezzi; Kamil Paruch; Michael P Dwyer; Ronald Doll; Amin Nomeir; William Windsor; Thierry Fischmann; Yaolin Wang; Martin Oft; Taiying Chen; Paul Kirschmeier; Emma M Lees
Journal:  Mol Cancer Ther       Date:  2010-07-27       Impact factor: 6.261

5.  Characterization of molecular and cellular functions of the cyclin-dependent kinase CDK9 using a novel specific inhibitor.

Authors:  T K Albert; C Rigault; J Eickhoff; K Baumgart; C Antrecht; B Klebl; G Mittler; M Meisterernst
Journal:  Br J Pharmacol       Date:  2014-01       Impact factor: 8.739

6.  3-Aminopyrazole inhibitors of CDK2/cyclin A as antitumor agents. 1. Lead finding.

Authors:  Paolo Pevarello; Maria Gabriella Brasca; Raffaella Amici; Paolo Orsini; Gabriella Traquandi; Luca Corti; Claudia Piutti; Pietro Sansonna; Manuela Villa; Betsy S Pierce; Maurizio Pulici; Patrizia Giordano; Katia Martina; Edward L Fritzen; Richard A Nugent; Elena Casale; Alexander Cameron; Marina Ciomei; Fulvia Roletto; Antonella Isacchi; GianPaolo Fogliatto; Enrico Pesenti; Wilma Pastori; Aurelio Marsiglio; Karen L Leach; Paula M Clare; Francesco Fiorentini; Mario Varasi; Anna Vulpetti; Martha A Warpehoski
Journal:  J Med Chem       Date:  2004-06-17       Impact factor: 7.446

7.  Cloning of murine CDK9/PITALRE and its tissue-specific expression in development.

Authors:  L Bagella; T K MacLachlan; R J Buono; M M Pisano; A Giordano; A De Luca
Journal:  J Cell Physiol       Date:  1998-11       Impact factor: 6.384

8.  Up-regulation of CDK9 kinase activity and Mcl-1 stability contributes to the acquired resistance to cyclin-dependent kinase inhibitors in leukemia.

Authors:  Yuh-Ying Yeh; Rong Chen; Joshua Hessler; Emilia Mahoney; Amy M Lehman; Nyla A Heerema; Michael R Grever; William Plunkett; John C Byrd; Amy J Johnson
Journal:  Oncotarget       Date:  2015-02-20

9.  CDK9 inhibition by dinaciclib potently suppresses Mcl-1 to induce durable apoptotic responses in aggressive MYC-driven B-cell lymphoma in vivo.

Authors:  G P Gregory; S J Hogg; L M Kats; E Vidacs; A J Baker; O Gilan; M Lefebure; B P Martin; M A Dawson; R W Johnstone; J Shortt
Journal:  Leukemia       Date:  2014-01-12       Impact factor: 11.528

10.  Discovery of a Small-Molecule Degrader of Bromodomain and Extra-Terminal (BET) Proteins with Picomolar Cellular Potencies and Capable of Achieving Tumor Regression.

Authors:  Bing Zhou; Jiantao Hu; Fuming Xu; Zhuo Chen; Longchuan Bai; Ester Fernandez-Salas; Mei Lin; Liu Liu; Chao-Yie Yang; Yujun Zhao; Donna McEachern; Sally Przybranowski; Bo Wen; Duxin Sun; Shaomeng Wang
Journal:  J Med Chem       Date:  2017-03-24       Impact factor: 7.446

View more
  57 in total

1.  Selective degradation of CDK6 by a palbociclib based PROTAC.

Authors:  Sandeep Rana; Mourad Bendjennat; Smit Kour; Hannah M King; Smitha Kizhake; Muhammad Zahid; Amarnath Natarajan
Journal:  Bioorg Med Chem Lett       Date:  2019-03-26       Impact factor: 2.823

2.  Proteolysis Targeting Chimeras (PROTACs) of Anaplastic Lymphoma Kinase (ALK).

Authors:  Chengwei Zhang; Xiao-Ran Han; Xiaobao Yang; Biao Jiang; Jing Liu; Yue Xiong; Jian Jin
Journal:  Eur J Med Chem       Date:  2018-03-27       Impact factor: 6.514

3.  Discovery of MD-224 as a First-in-Class, Highly Potent, and Efficacious Proteolysis Targeting Chimera Murine Double Minute 2 Degrader Capable of Achieving Complete and Durable Tumor Regression.

Authors:  Yangbing Li; Jiuling Yang; Angelo Aguilar; Donna McEachern; Sally Przybranowski; Liu Liu; Chao-Yie Yang; Mi Wang; Xin Han; Shaomeng Wang
Journal:  J Med Chem       Date:  2018-12-10       Impact factor: 7.446

4.  Optical Control of Small Molecule-Induced Protein Degradation.

Authors:  Yuta Naro; Kristie Darrah; Alexander Deiters
Journal:  J Am Chem Soc       Date:  2020-01-23       Impact factor: 15.419

5.  Synthesis of 7-benzylguanosine cap-analogue conjugates for eIF4E targeted degradation.

Authors:  Tanpreet Kaur; Arya Menon; Amanda L Garner
Journal:  Eur J Med Chem       Date:  2019-01-31       Impact factor: 6.514

Review 6.  PROteolysis TArgeting Chimeras (PROTACs) - Past, present and future.

Authors:  Mariell Pettersson; Craig M Crews
Journal:  Drug Discov Today Technol       Date:  2019-02-13

Review 7.  Kinase inhibitors: the road ahead.

Authors:  Fleur M Ferguson; Nathanael S Gray
Journal:  Nat Rev Drug Discov       Date:  2018-03-16       Impact factor: 84.694

Review 8.  Targeting Brd4 for cancer therapy: inhibitors and degraders.

Authors:  Yingchao Duan; Yuanyuan Guan; Wenping Qin; Xiaoyu Zhai; Bin Yu; Hongmin Liu
Journal:  Medchemcomm       Date:  2018-08-07       Impact factor: 3.597

Review 9.  Critical Assessment of Targeted Protein Degradation as a Research Tool and Pharmacological Modality.

Authors:  Milka Kostic; Lyn H Jones
Journal:  Trends Pharmacol Sci       Date:  2020-03-26       Impact factor: 14.819

10.  Chemical Genetic Screens Identify Kinase Inhibitor Combinations that Target Anti-Apoptotic Proteins for Cancer Therapy.

Authors:  Jacob I Contreras; Caroline M Robb; Hannah M King; Jared Baxter; Ayrianne J Crawford; Smit Kour; Smitha Kizhake; Yogesh A Sonawane; Sandeep Rana; Michael A Hollingsworth; Xu Luo; Amarnath Natarajan
Journal:  ACS Chem Biol       Date:  2018-04-05       Impact factor: 5.100

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.